Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Almirall S.A.
LBTSFAlmirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain. Address: Ronda General Mitre, 151, Barcelona, Spain, 08022
Analytics
WallStreetin tavoitehinta
12.49 EURP/E-suhde
–Osinkotuotto
1.72 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut LBTSF
Osinkoanalytiikka LBTSF
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
1 vuosiMaksusuhde 5 vuoden keskiarvo
112 %Osinkohistoria LBTSF
Osakkeen arvostus LBTSF
Talousasiat LBTSF
Tuloksia | 2019 | Dynamiikka |